Skye Bioscience, Inc.

SKYE is undervalued

NASDAQ · Healthcare

FAIR PRICE

40.5%upside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

$1.53

MARKET PRICE

$2.15

FAIR PRICE

$0.62

MARGIN

UNDERFAIROVER

COMMUNITY BUY ZONE

UNLOCKS AT 10

Where does the market buy SKYE?

No one has priced SKYE yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.

COMMUNITY MEDIAN

▓▓▓▓▓

BUYERS AT TODAY'S PRICE

▓▓ %

0/10 INVESTORS · 10 MORE TO UNLOCK

SET YOUR PRICE — iOS →ANDROID →

METRICS

P/E–

P/B–

P/S–

PEG–

DIV YIELD–

EV/EBITDA–

ROE–

ROIC–

NET MARGIN–

DEBT/EQ–

FCF YIELD–

MKT CAPN/A

NOW AVAILABLE

Get notified when SKYE's fair price changes

Push notifications when SKYE's valuation shifts. Available on iOS and Android.

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$1.72CONSERVATIVE ENTRY

$2.15FAIR PRICE

$1.53MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$1.72

Fair price × 0.80

DISTANCE

12.4%

Price to entry level

At the current price of $1.53, SKYE trades 12.4% below the conservative entry level of $1.72. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

SYNCING FEED ▌

P/E RATIO HISTORY

SYNCING FEED ▌

METHODOLOGY

How we calculate SKYE's fair price

Skye Bioscience, Inc.'s fair price of $2.15 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.53, SKYE trades 40.5% below its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting SKYE's risk profile.

RELATIVE · 30%

Comparing SKYE's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for SKYE, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate SKYE's fair value with your own inputs.

CALCULATOROpen →

SKYE DCF Calculator

Pre-filled with SKYE's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.

CALCULATOROpen →

Graham Number

Enter SKYE's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.

CALCULATOROpen →

P/E Ratio Calculator

Check how much investors pay per dollar of SKYE's earnings and compare it against sector benchmarks.

CALCULATOROpen →

EV/EBITDA Calculator

Compare SKYE against peers on a debt-adjusted basis using enterprise value and EBITDA.

LEARN MORE

What Is Fair Value?

How fair price is calculated and why it matters.

P/E Ratio Explained

What the price-to-earnings ratio tells you.

Margin of Safety

Warren Buffett's key investing principle.

Get full analysis, financials, and AI insights for SKYE.

Explore on Bulios

FAQ

What is the fair price of SKYE?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Skye Bioscience, Inc. is $2.15. At the current market price of $1.53, SKYE trades 40.5% below its calculated fair value.

Is SKYE overvalued or undervalued?+

Skye Bioscience, Inc. is currently undervalued based on our valuation model. The stock trades at $1.53, which is 40.5% below the fair price of $2.15.

What is the margin of safety for SKYE?+

With a 20% margin of safety applied to the fair price of $2.15, the conservative entry level for SKYE is $1.72. At the current market price of $1.53, the stock trades 12.4% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is SKYE's fair price updated?+

We update fair price calculations for SKYE daily after market close. The current fair price of $2.15 incorporates the latest market data and sector multiples.

What factors affect SKYE's fair price calculation?+

SKYE's fair price of $2.15 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)..

Is SKYE a good buy right now?+

At $1.53, SKYE trades 40.5% below our fair value estimate of $2.15. The stock is currently undervalued. Fair Price Index provides valuation data — always do your own research before investing.

Does SKYE pay dividends?+

SKYE does not currently pay a dividend.

RELATED STOCKS

Pfizer

Novo Nordisk

Johnson & Johnson

CVS

All healthcare stocks vs fair value →Today's most undervalued stocks →

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.